M
Martin Uhl
Researcher at Pasteur Institute
Publications - 6
Citations - 1859
Martin Uhl is an academic researcher from Pasteur Institute. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 3, co-authored 5 publications receiving 1607 citations. Previous affiliations of Martin Uhl include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
François Ghiringhelli,Lionel Apetoh,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Laetitia Aymeric,Laetitia Aymeric,Laetitia Aymeric,Yuting Ma,Yuting Ma,Yuting Ma,Carla Ortiz,Karim Vermaelen,Theocharis Panaretakis,Theocharis Panaretakis,Theocharis Panaretakis,Grégoire Mignot,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Jean-Luc Perfettini,Jean-Luc Perfettini,Jean-Luc Perfettini,Frédéric Schlemmer,Frédéric Schlemmer,Frédéric Schlemmer,Ezgi Tasdemir,Ezgi Tasdemir,Ezgi Tasdemir,Martin Uhl,Pierre Génin,Ahmet Civas,Bernhard Ryffel,Jean Kanellopoulos,Jürg Tschopp,Fabrice Andre,Fabrice Andre,Fabrice Andre,Rosette Lidereau,Nicole McLaughlin,Nicole M. Haynes,Mark J. Smyth,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +45 more
TL;DR: It is shown that dying tumor cells release ATP, which then acts on P2X7 purinergic receptors from DCs and triggers the NOD-like receptor family, pyrin domain containing-3 protein (NLRP3)-dependent caspase-1 activation complex ('inflammasome'), allowing for the secretion of interleukin-1 β (IL-1β).
Journal ArticleDOI
Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8 + T cells
Martin Uhl,Oliver Kepp,Oliver Kepp,Oliver Kepp,Hélène Jusforgues-Saklani,Hélène Jusforgues-Saklani,Jose Miguel Vicencio,Jose Miguel Vicencio,Jose Miguel Vicencio,Guido Kroemer,Guido Kroemer,Guido Kroemer,Albert Ml,Albert Ml,Albert Ml +14 more
TL;DR: It is predicted that targeting the autophagy cascade may provide a therapeutic strategy for achieving robust cross-priming of viral and tumor-specific CD8+ T cells.
Journal ArticleDOI
Antigen Persistence Is Required for Dendritic Cell Licensing and CD8+ T Cell Cross-Priming
Hélène Jusforgues-Saklani,Martin Uhl,Martin Uhl,Nathalie E. Blachere,Fabrice Lemaître,Olivier Lantz,Philippe Bousso,Deborah Braun,Deborah Braun,James J. Moon,Matthew L. Albert,Matthew L. Albert +11 more
TL;DR: By providing “extra help” in the form of dendritic cells (DCs) loaded with MHC class II peptide, it was possible to achieve robust activation of CD8+ T cells, implying that long-lived Ag is critical for efficient vaccination protocols in which the CD8- T cell response is helper-dependent.